Creating a new type of vaccine to prevent typhoid fever
Official title: Development of a low molecular weight synthetic Vi conjugate vaccine for salmonella typhi
Funded at Kj Biosciences, LLC · NIH-11076760 · Data updated 2026-11-12
This study is working on a new type of vaccine to help protect young children from typhoid fever, aiming to make it safer and more effective than current vaccines.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Kj Biosciences, LLC NIH-funded |
| Lab location | 1 site (College Station, United States) |
| Project start | April 18, 2024 |
| Project end | March 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $296,436 |
| NIH project number | 5R43AI184247-02 |
| Project ID | NIH-11076760 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals, particularly children over 6 months old, who are at risk of contracting typhoid fever.
✕Less likely to help
Patients who are already vaccinated against typhoid fever or those who do not live in areas where typhoid fever is prevalent may not benefit from this research.
What this research studies
This research focuses on developing a low molecular weight synthetic vaccine to protect against Salmonella typhi, the bacteria responsible for typhoid fever. The approach involves creating a conjugate vaccine that is more effective and has fewer side effects, particularly for young children. By using synthetic methods to produce the vaccine, the researchers aim to overcome challenges associated with traditional vaccine production, which can be complex and yield low amounts of the active ingredient. The goal is to ensure that the vaccine provides strong immunity without the drawbacks of existing options.
Why it matters
Potential benefit: If successful, this research could lead to a more effective vaccine that significantly reduces the incidence of typhoid fever, especially in vulnerable populations.
How similar studies have gone: Previous research on conjugate vaccines has shown promise in improving immunogenicity and effectiveness, suggesting that this approach could be successful.
Where this research is happening
-
Kj Biosciences, LLC
College Station, United States Active
Researchers
- Principal investigator: Ni, Yawei — Kj Biosciences, LLC
- Study coordinator: Ni, Yawei
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.